论文部分内容阅读
目的观察雾化布地奈德和口服强的松龙在慢性阻塞性肺疾病(COPD)急性加重期的临床疗效。方法60例COPD急性加重期住院患者随机分为3组,分别给予布地奈德雾化,强的松龙口服和空白对照治疗。观察3组患者在治疗前后的肺功能和动脉血气变化及不良反应情况。结果布地奈德组和强的松龙组的FEV1、FVC、PEFR和PaO2、PaCO2的改善程度均明显优于空白对照组,而布地奈德组和强的松龙组间差异无统计学意义,布地奈德组的不良反应明显少于强的松龙组,与空白对照组相仿。结论雾化布地奈德是COPD急性加重期激素治疗的有效选择。
Objective To observe the clinical efficacy of atomized budesonide and oral prednisolone in acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Sixty hospitalized patients with acute exacerbation of COPD were randomly divided into three groups. They were given budesonide nebulization, prednisolone oral and blank control respectively. Three groups of patients before and after treatment of lung function and arterial blood gas changes and adverse reactions. Results The improvement rates of FEV1, FVC, PEFR, PaO2 and PaCO2 in budesonide group and prednisolone group were significantly better than that in the blank control group, while there was no significant difference between budesonide group and prednisolone group. Adverse reactions in budesonide group were significantly less than those in prednisolone group, similar to those in blank control group. Conclusions Budesonide is an effective choice for hormone therapy in acute exacerbation of COPD.